ADVANCED DRUG DELIVERY SYSTEMS MARKET ANALYSIS

Advanced Drug Delivery Systems Market, By Type (Oral Drug Delivery System, Injection-Based Drug Delivery System, Inhalation/Pulmonary Drug Delivery System, Transdermal Drug Delivery System, Carrier Based Drug Delivery System, and Others), By Application (Cardiovascular Diseases, Oncology, Urology, Ophthalmology, Inflammatory Diseases, and Others), By Carrier Type (Liposomes, Nanoparticles, Microspheres, and Monoclonal Antibodies), By End User (Hospitals, Specialty Clinics, and Others), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa)

On January 2, 2024, Starton Therapeutics Inc., a biotechnology company, announced the launch of STARSILON, an innovative proprietary transdermal patch delivery platform. This advanced technology has the potential to broaden the range of active pharmaceutical ingredients that can be delivered through the skin. It utilizes a unique method to maintain concentration gradients, allowing for higher drug delivery rates and sustained therapeutic effects, particularly for challenging formulations.
In September 2023, the Advanced Research Projects Agency for Health (ARPA-H), part of the U.S. Department of Health and Human Services, launched a new program focused on developing technologies for real-time drug delivery and disease monitoring to enhance patient self-care. This initiative, called Resilient Extended Automatic Cell Therapies (REACT), aims to create systems that can automatically administer treatments and monitor health conditions from within the body.
In March 2022, Corium, Inc., a commercial-stage biopharmaceutical company, received the U.S. Food and Drug Administration (U.S. FDA) approval for its ADLARITY (donepezil transdermal system) as a treatment for patients with mild, moderate, or severe dementia of the Alzheimer's type. ADLARITY is one of the first and only once-weekly patches to continuously deliver consistent doses of donepezil through the skin.